Related Experiment Video
Updated: May 5, 2026

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
Alzheimer model chip with microglia BV2 cells
Ehsan Yazdanpanah Moghadam1,2, Nahum Sonenberg2, Muthukumaran Packirisamy3
1Optical-Bio Microsystems Laboratory, Micro-Nano-Bio Integration Center, Department of Mechanical and Industrial Engineering, Concordia University, Montreal, H3G 1M8, Canada.
Abstract:
Amyloid beta oligomers (AβO) are pivotal in Alzheimer's Disease (AD), cleared by microglia cells, as immune cells in the brain. Microglia cells exposed to AβO are involved with migration, apoptosis, phagocytosis, and activated microglial receptors through AβO, impacting cellular mechanobiological characteristics such as microglial adhesion strength to the underlying substrate. Herein, a label-free microfluidic device was used to detect advancing AD conditions with increasing AβO concentrations on microglia BV2 cells by quantitatively comparing the cell-substrate adhesion. The microfluidic device, acting as an AD model, comprises a single channel, which functions as a cell adhesion assay. To assess cell-substrate adhesion under different AβO concentrations of 1 µM, 2.5 µM, and 5 µM, the number of the cells attached to the substrate was counted by real-time microscopy when the cells were under the flow shear stress of 3 Pa and 7.5 Pa corresponding to Reynolds number (Re) of 10 and 25, respectively. The data showed that quantifying the cell-substrate adhesion using the microfluidic device could successfully identify conditions of advancing AβO concentrations. Our findings indicated that the increased incubation time with AβO caused reduced cell-substrate adhesion strength. Additionally, increased AβO concentration was another factor that weakened microglial interaction with the substrate. The quantification of cell-substrate adhesion using 3 Pa compared to 7.5 Pa clearly demonstrated advancing AβO in AD. This study using the chip provides an AD model for a deeper understanding mechanobiological behaviors of microglia exposed to AβO corresponding to diagnosed AD conditions under an in vitro microenvironment.
Insights
Amyloid beta oligomers (AβO) impact Alzheimer's Disease (AD) by altering microglia cell adhesion. This study used a microfluidic device to quantify AβO's effect on cell-substrate adhesion, revealing reduced adhesion with increased AβO concentration and incubation time.
Area of Science:
- Neuroscience
- Biotechnology
- Cell Biology
Background:
- Amyloid beta oligomers (AβO) are key players in Alzheimer's Disease (AD) pathogenesis.
- Microglia, the brain's immune cells, interact with AβO, influencing their mechanobiological properties.
- Altered microglial adhesion strength is a potential biomarker for AD progression.
Purpose of the Study:
- To develop and utilize a label-free microfluidic device as an in vitro model for detecting advancing AD conditions.
- To quantitatively assess the impact of varying AβO concentrations on microglial cell-substrate adhesion strength.
- To understand the mechanobiological changes in microglia upon exposure to AβO.
Main Methods:
- A microfluidic device with a single channel was employed as a cell adhesion assay.
- Microglia BV2 cells were exposed to different AβO concentrations (1 µM, 2.5 µM, 5 µM).
- Cell-substrate adhesion was quantified in real-time under controlled flow shear stress (3 Pa and 7.5 Pa) using microscopy.
Main Results:
- The microfluidic device successfully identified advancing AβO concentrations.
- Increased incubation time with AβO led to reduced cell-substrate adhesion strength.
- Higher AβO concentrations further weakened the adhesion of microglia to the substrate.
Conclusions:
- Quantifying microglial cell-substrate adhesion in a microfluidic system serves as a viable method for modeling AD.
- Mechanobiological changes in microglia, specifically adhesion strength, are sensitive indicators of AβO exposure and AD progression.
- This approach offers a deeper understanding of microglia-AβO interactions in an in vitro AD model.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology

